• Users Online: 154
  • Print this page
  • Email this page
Year : 2020  |  Volume : 3  |  Issue : 1  |  Page : 21-31

Cell therapy of critical limb ischemia: A review of preclinical and clinical research in China

Center of Laboratory Medicine, Union Hospital of Fujian Medical University, Fuzhou, Fujian, China

Correspondence Address:
Dr. Lianming Liao
Center of Laboratory Medicine, Union Hospital of Fujian Medical University, No. 29, Xinquan Road, Fuzhou, Fujian 350001
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/VIT.VIT_7_20

Rights and Permissions

Critical limb ischemia (CLI) is the advanced stage of peripheral artery diseases and is characterized by limb pain. Current available treatments for CLI include pharmacological agents, bypass surgery, and endovascular therapy. When these conventional therapies fail, some patients may eventually suffer from amputation because of long-term blood flow insufficiency to the affected extremity. Novel therapeutic approaches are emergently needed. At present, proangiogenic gene/protein therapies and stem cell-based proangiogenic therapies have been proposed, and the promising results have been reported. Gene-modified stem cells and pretreated stem cells have been evaluated in the animal models. Proper bioscaffolds are also used to increase the survival and engraftment of delivered stem cells. Here, we address the current situation of stem cell research for CLI in China.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded143    
    Comments [Add]    
    Cited by others 1    

Recommend this journal